Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoimmunotherapy with blood-brain barrier opening for primary central nervous system lymphoma
2014-005015-16Phase 2Active
- Sponsor
- Oulu University Hospital
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, carboplatin, methotrexate, cyclophosphamide and etoposide in primary central nervous system lymphoma (PCNSL), sponsored by Oulu University Hospital. Primary endpoints: Proportion of patients alive at 2 years and Proportion of patients alive at 5 years. Started Dec 2016; status: active.
02
Drugs
rituximabcarboplatinmethotrexatecyclophosphamideetoposide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2014-005015-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005015-16.